Background: Promising results of thoracic endovascular aortic repair (TEVAR) in patients with complicated type B aortic dissection (TBAD) have been well documented. However, whereas early results have led many to hypothesize a benefit of TEVAR in uncomplicated patients, the natural history of TEVAR after the treatment of TBAD has yet to mature. In this review, we evaluated the available data to investigate whether longer term TEVAR warrants enthusiasm for all comers with TBAD.
Thoracic endovascular aortic repair (TEVAR) has quickly become the primary treatment modality for complicated acute type B aortic dissection (TBAD). With morbidity and mortality rates significantly improved compared with traditional open surgical repair, TEVAR is now the first choice in the management of these acutely ill patients. 1 The success of TEVAR in the treatment of complicated TBAD has led many to hypothesize that the treatment modality may also provide benefit to patients with uncomplicated TBAD. 2 As these patients, by definition, have no symptoms or evidence of malperfusion, the aim of intervention would be the prevention of late aortic morbidity, specifically aneurysmal degeneration and rupture. In this review, we aimed to use the existing data to answer the following question: Does TEVAR stabilize the aorta and prevent aneurysmal degeneration in patients with TBAD?
METHODS
A systematic review of the literature was performed by two independent reviewers according to guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. Citations in the MEDLINE database up to September 2016 were reviewed using the PubMed interface. A combination of the search terms "aorta," "aortic," "aneurysmal degeneration," "dissection," "endovascular," "expansion," "remodeling," "remodel," "TEVAR," and "type B" was used to identify relevant papers.
Studies were included if they met the following criterion: assessment of changes in total aortic diameter or volume after TEVAR for TBAD. Only English-language papers and reports examining human subjects were included. Studies reporting only change in average or mean aortic diameter were excluded as this method of reporting change masks significant change when it occurs in opposite directions. All appropriate studies including 20 or more patients were included. No additional limits were placed on publication date or journal. Only published data were included in this review. Institutional Review Board approval was waived for this review as only previously published data were used.
Specific information collected included the following: study type, chronicity of dissections, presence of complicated factors, number of patients, and duration of follow-up. The primary outcomes reviewed were the percentage of patients experiencing thoracic aortic growth on follow-up and the percentage of patients experiencing abdominal aortic growth on follow-up.
RESULTS
On initial search, 84 publications were identified for possible inclusion. After screening, 37 studies were downloaded in full text for review, and 17 met all criteria for inclusion. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Specifically, 12 publications [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] were excluded because the percentage of patients with aneurysmal degeneration was not reported, with 10 publications [19] [20] [21] [22] [23] [24] [25] 27, 28, 30 excluded specifically because only mean aortic diameter changes were reported. A list of included publications can be found in Table I . A flow diagram detailing this systematic review process can be seen in the Fig. Thoracic aortic growth. All but one of the 17 publications reported the percentage of patients exhibiting thoracic aortic growth during the study period. This number ranged from 6.6% to 84%. These studies included both acute and chronic dissection patients as well as both complicated and uncomplicated patients. Both prospective and retrospective data were included.
Abdominal aortic growth. Overall, the fate of the abdominal aorta after TEVAR for TBAD is seldom reported. Only six studies reported the percentage of patients with growth in the abdominal aorta. Rates of growth in the abdominal aorta ranged from 10% to 54%. All of the studies reporting abdominal aortic measurements included complicated patients.
Acute aortic dissection. The studies reporting data of patients treated only for acute aortic dissection are summarized in Table II . Acute aortic dissection was uniformly defined as a dissection treated within 14 days of symptom onset. Table II includes data of the acute patients from three of the studies reporting both acute and chronic as these studies separated the acute and chronic patients in their results. 4, 5, 14 Rates of thoracic aortic growth ranged from 8% to 63%, whereas rates of abdominal growth ranged from 8% to 47%.
Chronic aortic dissection. Table III summarizes the data of chronic patients only and also includes data specific to chronic patients from the three studies that reported their acute and chronic data separately. 4, 5, 14 Thoracic growth was seen in 7% to 25% of patients across these studies. Abdominal growth was noted in only three studies and ranged in frequency from 7% to 45%.
Defining and identifying growth. Table I includes, when available, the cutoff each study used to define aortic growth. All three studies measuring aortic volume used a cutoff of 10% change to define growth. 7, 11, 13 The majority of studies reporting diameter change defined growth as a change of either >5 mm 3,4,14 or $5 mm. 2, 6, 8, 13, 15, 16 Five studies did not define growth at all.
5,9,10,12,17
Further differences were noted in the methods and locations of measurement performed in each study. Some studies noted using software to centerline the aorta before measurement; others did not. Protocols for measurement points ranged from unspecified to eight specific points throughout the aorta. Studies measured varying combinations of true lumen, false lumen, and total aortic diameter. No two protocols were alike.
Follow-up periods. The duration of follow-up was different for each study. Whereas some studies had a set end point, others observed their patients as long as possible, reporting average follow-up durations and ranges or standard deviations. When the only follow-up information available was average time and range or standard deviation, this was reported in Tables I-III . If a data point was chosen for reporting, however, the number of patients with follow-up data available at that time was listed. None of the studies had follow-up 
DISCUSSION
Medical management of acute TBAD is associated with an early mortality rate of 7% to 9%. 1, 12 Successful blood pressure control allows the remainder of these patients to return home, where their acute dissection develops into a chronic disease process. The 5-year survival, estimated between 60% and 80%, is hardly encouraging.
12,31
In the first year, more than one in four of these patients will exhibit aneurysmal degeneration of the aorta, with 20% requiring intervention. 12 These statistics have prompted many to wonder whether early TEVAR in uncomplicated dissection patients will prevent late complications, specifically aneurysmal degeneration and rupture. The rate of aneurysmal degeneration in patients with acute TBAD managed with medical therapy alone is significant. The International Registry of Acute Aortic Dissection database shows that after an 8.7% early mortality, patients go on to experience a 27.5% 1-year risk of aneurysmal degeneration and a 20.6% risk of reintervention. 1 Kaplan-Meier estimates of long-term outcomes in that same population of patients predicted a risk of aneurysmal degeneration in 73% of patients at 5 years. 12 In the 68 patients managed with optimal medical therapy alone in the Investigation of Stent Grafts in Aortic Dissection (INSTEAD) trial, 46% of patients experienced "disease progression" at 5 years, defined as aortaspecific death, crossover to the TEVAR group, or need for secondary procedures, although rates of aneurysmal degeneration specifically were not reported. 25 In the medical therapy group of the Acute Dissection Stent Grafting or Best Medical Treatment (ADSORB) trial, 45% of patients saw aneurysmal degeneration at 1 year. 2 Although aortic remodelingdfalse lumen regression and expansion of the true lumendis thought to correlate with improved outcomes, data on changes in the true and false lumen directly affecting aorta-related survival are lacking. Maximum aortic diameter, however, has been shown to predict aortic rupture and death, with aneurysmal degeneration to >60 mm conferring an 11.8% yearly risk of death. 32 It is therefore important, in evaluating any intervention in the treatment of uncomplicated TBAD patients, to specifically discuss the risk of aortic dilation. For this review, we have excluded any studies using only changes in mean aortic diameter as a study end point. One assumes that patients experiencing positive aortic remodeling also show regression in total aortic diameter. When averaged, however, these patients will mathematically negate patients with aneurysmal degeneration, and the mean aortic diameter of the group will be unchanged. This leads to blended data and a falsely assumed stability. We believe that this method of reporting unintentionally overlooks significant rates of post-TEVAR aortic growth.
For example, in the ADSORB trial, 61 patients with acute, uncomplicated TBAD were randomized to TEVAR and medical therapy or medical therapy alone. 2 In this study, the average diameters of the true lumen, false lumen, and total aorta are reported at both the start of the study and 1 year. At the start, the medical therapy and TEVAR groups had average diameters that were similar. At 1 year, however, the average false lumen diameter was smaller in the TEVAR group, and the average true lumen diameter was larger in the TEVAR group. The reported conclusion of these data was that "reduction of [false lumen] diameter is induced by the stent graft." However, this positive remodeling does not correlate with prevention of aortic growth, as 11 of the 31 patients treated with TEVAR, like 14 of the 30 patients treated with medical therapy alone, exhibited aneurysmal degeneration at 1 year (37% vs 45%; P ¼ .5). It is difficult to say, at this point, how prevalent this reporting phenomenon is in the literature. The data presented in the studies included in this review show that after TEVAR, dissection patients continue to have a substantial risk of aneurysmal degeneration over time. In the thoracic aorta, this risk seems to approach or to equal the risk in patients treated with medical therapy alone. The few publications that studied the abdominal aorta after TEVAR found that there is aortic growth in a significant number of patients, and this risk may be even higher than the risk of growth in the thoracic aorta. It can be stated, therefore, that TEVAR does not prevent aneurysmal degeneration of the thoracic or abdominal aorta in TBAD patients. This fact firmly supports the idea that aortic dissection is a complex, chronic disease process requiring long-term screening and management, even after TEVAR.
Although it is possible that TEVAR can alter the rate or severity of aneurysmal degeneration, the current body of literature does not provide us with that information, and on the basis of these data alone, it is impossible to calculate a numerical risk of aneurysmal degeneration in either group of patients or to compare those risks. Differences in methods of tracking and reporting follow-up make it difficult to draw any conclusions about graded growth over time across studies. Some of the studies with longer average follow-up appear to have lower rates of aneurysmal degeneration. However, the two studies with multiple follow-up points in the same populations of patients 11, 12 suggest continuation of growth over time. Future research requires transparent and consistent reporting of follow-up to standardize these trends and to compare studies. There are data, by some authors, identifying anatomic factors that may place patients at higher risk of aneurysmal degeneration after the diagnosis of TBAD. [33] [34] [35] [36] Multiple or large intimal tears, patent false lumen, and large initial aortic diameter have all been shown to increase risk of late growth. These potential risk factors may help us identify patients who may benefit from earlier intervention, if they are properly studied prospectively in the future.
Limitations. The most significant limitation of this review is the heterogeneity of reported data found in the literature. The pooling of patient data even from the 17 included studies that met criteria is therefore ill-advised. The 12 publications that were excluded highlight this limitation further, as the end point desired, percentage of patients with aneurysmal degeneration, was present in those data sets but not reported.
Specifically, the definition of aortic growth and the location of measurements varied significantly between studies. Differences noted in the studies that looked at both the thoracic and abdominal aorta prove the value of assessing the aorta in multiple locations. A standardized reporting system for patients with TBAD would allow us to compare and to combine data across multiple studies to strengthen our understanding of this complex disease process.
The only included study examining solely uncomplicated TBAD patients was the ADSORB trial. 2 All of the other studies included complicated patients, and no study reported data individually for patient groups based on symptom status. Therefore, it is impossible to use these combined data to look at uncomplicated patients alone. However, the data from the ADSORB trial, in which 37% of patients experienced growth after TEVAR, reemphasize a significant risk of growth in these patients.
CONCLUSIONS
Based on the available data to date, TEVAR for TBAD did not prevent aneurysmal degeneration of the thoracic or abdominal aorta. More long-term data are necessary to clearly define the risk of aortic growth after medical therapy or TEVAR in specific groups of patients. The sobering rates of growth after TEVAR for TBAD should give pause to those who espouse the treatment of uncomplicated patients. Given the variability of manuscript reporting styles for TBAD, the development of reporting standards is necessary to homogenize available data and to strengthen our understanding of this complex disease process. 
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